Friday, June 10, 2011

XMRV and Prostate Cancer


XMRV Discovery and Prostate Cancer Related Research

David E. Kang1,2, Michael C. Lee1,2, Jaydip Das Gupta2, Eric A.
Klein1,2,3, and Robert H. Silverman2,3

1Glickman Urological and Kidney Institute, 2Department of Cancer
Biology, Lerner Research Institute, and 3Taussig Cancer Center,
Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195

*Corresponding author: Robert H. Silverman, Cleveland Clinic, 9500
Euclid Avenue NB40, Cleveland, OH 44195. Telephone: 216-445-9650, Fax:
216-445- 6269, e-mail:

Xenotropic murine leukemia virus-related virus (XMRV) was first
reported in 2006 in a study of human prostate cancer patients with
genetic variants of the antiviral enzyme, RNase L.
investigations in North America, Europe, Asia and Africa have either
observed or failed to detect XMRV in patients [prostate cancer,
chronic fatigue syndrome-myalgic encephalomyelitis (CFS-ME),
immunosuppressed with respiratory tract infections] or normal, healthy
control individuals. The principal confounding factors are the near
ubiquitous presence of mouse derived reagents, antibodies and cells,
and often XMRV itself, in laboratories. XMRV infects and replicates
well in many human cell lines, but especially in certain prostate
cancer cell lines.
XMRV also traffics to prostate in a non-human
primate model of infection. Here we will review the discovery of XMRV
and then focus on prostate cancer related research involving this
intriguing virus.

No comments: